×
About 60,652 results

ALLMedicine™ Pancreatic Cancer Center

Research & Reviews  29,159 results

Five gene signatures were identified in the prediction of overall survival in resectabl...
https://doi.org/10.1186/s12893-020-00856-y
BMC Surgery; Wu C, Wu Z et. al.

Sep 18th, 2020 - Although genes have been previously detected in pancreatic cancer (PC), aberrant genes that play roles in resectable pancreatic cancer should be further assessed. Messenger RNA samples and clinicopathological data corrected with PC were downloaded...

Perception of cancer in patients diagnosed with the most common gastrointestinal cancers.
https://doi.org/10.1186/s12904-020-00650-w
BMC Palliative Care; Czerw A, Religioni U et. al.

Sep 18th, 2020 - Gastrointestinal cancers, including colorectal cancer, stomach cancer and pancreatic cancer are among the most common cancers in Poland. Cancer patients usually assess their quality of life much worse than the general population, while negative em...

EphA2‑enriched exosomes promote cell migration and are a potential diagnostic serum mar...
https://doi.org/10.3892/mmr.2020.11384
Molecular Medicine Reports; Wei Q, Wei L et. al.

Sep 18th, 2020 - Pancreatic cancer (PC) is the fourth most common cause of cancer‑related mortality worldwide and is characterized by high invasiveness and early metastasis. To identify novel diagnostic markers, the present study aimed to understand the mechanism ...

Curcumin enhances anti‑cancer efficacy of either gemcitabine or docetaxel on pancreatic...
https://doi.org/10.3892/or.2020.7713
Oncology Reports; Liu P, Ying Q et. al.

Sep 18th, 2020 - Curcumin is a natural compound extracted from turmeric (Curcuma longa), which has been reported to be a promising anti‑cancer drug in various human cancers. However, the effects of combination treatment of curcumin with gemcitabine or docetaxel on...

Modulation of protein S and growth arrest specific 6 protein signaling inhibits pancrea...
https://doi.org/10.3892/or.2020.7689
Oncology Reports; Pilli VS, Datta A et. al.

Sep 18th, 2020 - Thrombotic complications and hypercoagulopathies are commonly associated with the progression of pancreatic ductal adenocarcinoma (PDAC). Although the mechanistic link between the two phenomena is uncertain, there is evidently an increase in proco...

see more →

Guidelines  85 results

Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practic...
https://doi.org/10.1016/j.prro.2019.06.016
Practical Radiation Oncology; Palta M, Godfrey D et. al.

Sep 2nd, 2019 - This guideline systematically reviews the evidence for treatment of pancreatic cancer with radiation in the adjuvant, neoadjuvant, definitive, and palliative settings and provides recommendations on indications and technical considerations. The Am...

Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recomm...
https://doi.org/10.1001/jama.2019.10232
JAMA , Owens DK et. al.

Aug 6th, 2019 - Pancreatic cancer is an uncommon cancer with an age-adjusted annual incidence of 12.9 cases per 100 000 person-years. However, the death rate is 11.0 deaths per 100 000 person-years because the prognosis of pancreatic cancer is poor. Although its ...

Screening for Pancreatic Cancer Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
https://jamanetwork.com/journals/jama/fullarticle/2740726
JAMA

Aug 5th, 2019 - Importance Pancreatic adenocarcinoma is the third most common cause of cancer death among men and women in the United States. Objective To systematically review benefits and harms of screening for pancreatic adenocarcinoma to inform the US Prev...

Screening for Pancreatic Cancer US Preventive Services Task Force Reaffirmation Recommendation Statement
https://jamanetwork.com/journals/jama/fullarticle/2740727
JAMA

Aug 4th, 2019 - Importance Pancreatic cancer is an uncommon cancer with an age-adjusted annual incidence of 12.9 cases per 100 000 person-years. However, the death rate is 11.0 deaths per 100 000 person-years because the prognosis of pancreatic cancer is poor. A...

see more →

Drugs  87 results see all →

Clinicaltrials.gov  30,465 results

Five gene signatures were identified in the prediction of overall survival in resectabl...
https://doi.org/10.1186/s12893-020-00856-y
BMC Surgery; Wu C, Wu Z et. al.

Sep 18th, 2020 - Although genes have been previously detected in pancreatic cancer (PC), aberrant genes that play roles in resectable pancreatic cancer should be further assessed. Messenger RNA samples and clinicopathological data corrected with PC were downloaded...

Perception of cancer in patients diagnosed with the most common gastrointestinal cancers.
https://doi.org/10.1186/s12904-020-00650-w
BMC Palliative Care; Czerw A, Religioni U et. al.

Sep 18th, 2020 - Gastrointestinal cancers, including colorectal cancer, stomach cancer and pancreatic cancer are among the most common cancers in Poland. Cancer patients usually assess their quality of life much worse than the general population, while negative em...

EphA2‑enriched exosomes promote cell migration and are a potential diagnostic serum mar...
https://doi.org/10.3892/mmr.2020.11384
Molecular Medicine Reports; Wei Q, Wei L et. al.

Sep 18th, 2020 - Pancreatic cancer (PC) is the fourth most common cause of cancer‑related mortality worldwide and is characterized by high invasiveness and early metastasis. To identify novel diagnostic markers, the present study aimed to understand the mechanism ...

Curcumin enhances anti‑cancer efficacy of either gemcitabine or docetaxel on pancreatic...
https://doi.org/10.3892/or.2020.7713
Oncology Reports; Liu P, Ying Q et. al.

Sep 18th, 2020 - Curcumin is a natural compound extracted from turmeric (Curcuma longa), which has been reported to be a promising anti‑cancer drug in various human cancers. However, the effects of combination treatment of curcumin with gemcitabine or docetaxel on...

Modulation of protein S and growth arrest specific 6 protein signaling inhibits pancrea...
https://doi.org/10.3892/or.2020.7689
Oncology Reports; Pilli VS, Datta A et. al.

Sep 18th, 2020 - Thrombotic complications and hypercoagulopathies are commonly associated with the progression of pancreatic ductal adenocarcinoma (PDAC). Although the mechanistic link between the two phenomena is uncertain, there is evidently an increase in proco...

see more →

News  769 results

AstraZeneca-Merck's Lynparza wins EU approval for pancreatic cancer
https://www.reuters.com/article/us-astrazeneca-lynparza/astrazeneca-mercks-lynparza-wins-eu-approval-for-pancreatic-cancer-idUSKBN2490OI

Jul 8th, 2020 - FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London, April 28, 2014. REUTERS/Stefan Wermuth/File Photo (Reuters) - AstraZeneca Plc and Merck & Co Inc said on Wednesday their blockbuster cancer treatment Lynpa...

Israeli medical device maker Alpha Tau raises $26 million to fund trials
https://www.reuters.com/article/uk-tech-fundraising-alpha-tau/israeli-medical-device-maker-alpha-tau-raises-26-million-to-fund-trials-idUSKBN23B1NX

Jun 4th, 2020 - JERUSALEM (Reuters) - Israeli medical device maker Alpha Tau Medical said on Thursday it raised $26 million in a funding round from investors including Shavit Capital, Medison Ventures and OurCrowd to help finance global clinical trials. Alpha Tau...

AstraZeneca scores twin drug approvals alongside vaccine progress
https://www.reuters.com/article/us-astrazeneca-ema-lynparza/astrazeneca-scores-twin-drug-approvals-alongside-vaccine-progress-idUSKBN2381EV

Jun 1st, 2020 - (Reuters) - Britain’s AstraZeneca has clinched expanded regulatory backing for two medications, including one for blockbuster cancer treatment Lynparza, in a development pipeline that now includes a possible coronavirus vaccine. Lynparza received ...

Molecularly guided therapy in pancreatic cancer: Untapped potential and the ‘bright future’ ahead
https://www.mdedge.com/gihepnews/article/218713/gastroenterology/molecularly-guided-therapy-pancreatic-cancer-untapped?channel=39703
Will Pass, MDedge News

Mar 10th, 2020 - Molecularly guided treatments may extend survival by more than a year for patients with pancreatic cancer who have actionable molecular alterations, according to a retrospective analysis of almost 2,000 patients in the Know Your Tumor registry. Wh.

Preoperative chemoradiotherapy failed to boost overall survival in pancreatic cancer
https://www.mdedge.com/gihepnews/article/218405/gastroenterology/preoperative-chemoradiotherapy-failed-boost-overall?channel=27970
Caleb Rans, MDedge News

Mar 4th, 2020 - Preoperative chemoradiotherapy failed to improve overall survival among patients with resectable or borderline resectable pancreatic cancer, according to findings from a phase 3 trial. On the other hand, preoperative chemoradiotherapy improved dis.

see more →

Patient Education  87 results see all →